Live
FierceBiotechThousands of clinical trial sites impacted by Middle East conflict: reportFierceBiotechDrug combo treats multiple cancers with ‘paradox’ mutation in miceFierceBiotechValneva CEO on Pfizer-partnered Lyme vaccine: Why a phase 3 miss doesn’t tell the whole storyAgilentSynthego Welcomes Supreme Court Order Finalizing Invalidation of Agilent CRISPR Patents - PR NewswireEndpoints NewsMaking custom CRISPR therapies could be harder than initially thoughtEndpoints NewsTo counter China, FDA chief wants to speed new drug trial processLonza NewsLonza Group (SWX:LONN) Is Up 5.8% After 25% Dividend Hike And Board Refresh - Has The Bull Case Changed? - simplywall.stAgilentAgilent Technologies Announces Cash Dividend of 12 Cents per Share - YahooBioPharma DiveFDA approves Lilly obesity pill, triggering battle with Novo NordiskEndpoints NewsNovo cuts 400 jobs in Indiana as Scholar Rock refiles drug linked to the factoryCellRational discovery of therapeutic PAK1 allosteric activatorsCellA 3D morphogenetic blueprint for metastatic outgrowth in breast cancer
Endpoints News Apr 1, 2026

Making custom CRISPR therapies could be harder than initially thought

Making custom CRISPR therapies could be harder than initially thought

Original
Body unavailable. Use the original source.

Directory

59 All